vaccines – UF Innovate https://innovate.research.ufl.edu Building business on innovation Tue, 12 Aug 2025 04:32:03 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://innovate.research.ufl.edu/wp-content/uploads/favicon-blue_1.png vaccines – UF Innovate https://innovate.research.ufl.edu 32 32 Oragenics Extends Collaboration To Develop Vaccines Against Future Variants of Coronaviruses https://innovate.research.ufl.edu/oragenics-extends-collaboration-to-develop-vaccines-against-future-variants-of-coronaviruses/ Fri, 08 Apr 2022 00:00:00 +0000 https://scaddev1.com/oragenics-extends-collaboration-to-develop-vaccines-against-future-variants-of-coronaviruses/ UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc. announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that enables Oragenics to pursue an intranasal vaccine designed to protect against future variants of coronaviruses. The NRC cell expression technologies provide Oragenics with a platform that can generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern. This platform could allow production of cell lines within six to eight weeks of spike gene sequence availability, compared with six to nine months for traditional production of such cell lines. The NRC technologies, developed with support from the NRC’s Pandemic Response Challenge program, will expedite the evaluation of future intranasal vaccine candidates in preclinical and clinical studies.

Learn more about Oragenics Extends Collaboration To Develop Vaccines Against Future Variants of Coronaviruses ]]> Resilience To Get $164M for Site Expansion https://innovate.research.ufl.edu/resilience-164m-site-expansion-ontario/ Fri, 28 May 2021 00:00:00 +0000 https://scaddev1.com/resilience-164m-site-expansion-ontario/ Resilience, a recently launched manufacturing and technology company for biologics and advanced therapies that recently acquired UF startup and UF Innovate | Sid Martin Biotech graduate Ology Bioservices, will receive a $164-million investment from the Canadian government to modernize and expand the biomanufacturing site of its Mississauga, Ontario, Canada-based subsidiary, Resilience Biotechnologies Inc. (RBI).

This project will help increase manufacturing capacity for vaccines and therapeutics, including novel technologies such as mRNA that are now being used to fight COVID-19.

Read more about Resilience To Get $164M for Site Expansion.
Resilience Acquires Biologics Manufacturing Company Ology Bioservices
]]>